N,N-Diethyl-β-brom-propionamid | 5437-82-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N,N-Diethyl-β-brom-propionamid
• 英文别名: N,N-Diethyl-3-brom-propionamid；3-Bromo-n,n-diethylpropanamide
• CAS: 5437-82-1
• 化学式: C₇H₁₄BrNO
• 分子量: 208.098
• InChiKey: MLJKRCKEPBMCIG-UHFFFAOYSA-N

物化性质

• 沸点：
  95-97 °C(Press: 3.0 Torr)
• 密度：
  1.287±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N,N-Diethyl-β-brom-propionamid 生成 N-ethoxycarbonyl-N-phenyl-β-alanine diethylamide
  参考文献：
  名称：

  Larizza; Brancaccio, Gazzetta Chimica Italiana, 1959, vol. 89, p. 2402,2404

  摘要：

  DOI：
• 作为产物：
  描述：

  二乙胺盐酸盐 、 3-溴丙酰氯 在 potassium carbonate 作用下， 生成 N,N-Diethyl-β-brom-propionamid
  参考文献：
  名称：

  Important Role of the 3-Mercaptopropionamide Moiety in Glutathione:  Promoting Effect on Decomposition of the Adduct of Glutathione with the Oxoammonium Ion of TEMPO

  摘要：

  Cyclic voltammetry of TEMPO in aqueous 0.1 M NaOH in the presence of glutathione (GSH) or cysteine (Cys) indicated the following points: (i) Both of the thiols rapidly formed adducts 3 with oxoammonium ion 1 anodically generated from TEMPO. (ii) 3 generated from GSH entered a succeeding reaction that generated N-oxide anion 2(-) (the reduced TEMPO). (iii) 3 produced from Cys remained intact over the time scale of voltammetry. A structural feature of GSH was considered to contribute to the observed behavior of this tripeptide. Possible structural features were evaluated by screening various thiols on the basis of whether they provided GSH-like voltammetric results. The 3-mercaptopropionamide group with an amide hydrogen in GSH was determined to be responsible for the observed difference between GSH and Cys. The likely function is to transform 3 from GSH into a 5-imino-1,2-oxathiolane intermediate, thereby releasing 2(-). Product analysis for reactions of model thiols representing GSH and Cys with 1 provided support for this argument and suggested that the reaction of GSH or Cys with 1 would produce the corresponding disulfides, regardless of whether a five-membered ring intermediate was formed. The proposed function of the 3-mercaptopropionamide moiety of GSH may provide useful insight for the molecular design of exogenous thiol compounds as novel drugs for the treatment of GSH-depletion-related disorders.

  DOI：

  10.1021/jo050783c

文献信息

• [EN] SIGMA RECEPTOR BINDERS<br/>[FR] LIANTS DE RÉCEPTEUR SIGMA
  申请人：UNIV TEXAS

  公开号：WO2017190107A1

  公开（公告）日：2017-11-02

  Provided herein, inter alia, are compounds and methods of treating diseases including cancer, neurological disease, alcohol withdrawal, depression and anxiety, traumatic brain injury, and neuropathic pain.

  本文提供了治疗疾病的化合物和方法，包括癌症、神经系统疾病、酒精戒断、抑郁和焦虑、创伤性脑损伤以及神经病痛。
• LSD Analogs
  作者：Kenneth J. Liska、James L. Johnson、James P. Mastrian、Marie L. Steenberg

  DOI：10.1002/jps.2600551010

  日期：1966.10

  Patterned after a fragment of the LSD molecule, the ethyl esters, simple amides, and N , N -diethylamides of N -methyl- N - p -(and m -)methoxyphenyl- β -alanine were prepared for evaluation as psychotomimetics. Of five compounds tested, three exhibited some degree of antiserotonin activity in the isolated rat fundus preparation. One of these three appeared also to be anticholinergic.

  在LSD分子的片段之后进行图案化，制备N-甲基-N-p-（和m-）甲氧基苯基-β-丙氨酸的乙酯，简单酰胺和N，N-二乙酰胺，以作为拟精神病药物进行评估。在测试的五种化合物中，三种在分离的大鼠眼底制剂中显示出一定程度的抗血清素活性。这三者之一似乎也是抗胆碱能的。
• SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS
  申请人：ALLERGAN, INC.

  公开号：US20130252984A1

  公开（公告）日：2013-09-26

  The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

  本发明涉及新型硫衍生物，其制备过程，含有它们的药物组合物以及它们作为药物的用途，用作趋化因子受体的调节剂。
• Sulfur derivatives as chemokine receptor modulators
  申请人：Allergan, Inc.

  公开号：US08822530B2

  公开（公告）日：2014-09-02

  The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.

  本发明涉及新型硫衍生物，其制备方法，含有它们的制药组合物以及它们作为药物调节化学因子受体的用途。
• Targeting σ2R/TMEM97 with novel aminotetralins
  作者：Michael D. Wood、James J. Sahn、Stephen F. Martin

  DOI：10.1016/j.ejmech.2022.114696

  日期：2022.12

  and therapy, the sigma 2 receptor (σ2R) has recently been implicated in several disorders of the central nervous system (CNS). It remained a poorly characterized target until we identified it as the transmembrane protein 97 (TMEM97). As part of a program to identify novel compounds that bind with high affinity and selectivity to σ2R/TMEM97 relative to the sigma 1 receptor (σ1R) and other CNS proteins

  最初与癌症诊断和治疗相关的 sigma 2 受体 (σ 2 R) 最近与几种中枢神经系统 (CNS) 疾病有关。在我们将其鉴定为跨膜蛋白 97 (TMEM97) 之前，它仍然是一个表征不佳的靶标。作为识别相对于 sigma 1 受体 (σ 1 R) 和其他 CNS 蛋白以高亲和力和选择性与 σ 2 R/TMEM97结合的新化合物的计划的一部分，我们采用支架简化策略来设计新的哌嗪组-基于我们之前开发的类似去甲苯并吗啉的取代氨基四氢萘。JVW-1601被鉴定为具有高亲和力 ( K i = 5.5 nM) 和选择性 (36 倍) 对于 σ 2 R/TMEM97 与 σ 1 R。对该化合物的几个结构区域中的结构-活性关系 (SAR) 进行了扩展研究，在由此制备的配体中，许多σ 2 R/TMEM97 的K i值 < 20 nM ，选择性比 σ 1 R高 20 倍以上。确定了增强 σ 2 R/TMEM97